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Abstract
Background: Predicting future prevalence of any opportunistic infection (OI) among persons infected with the
human immunodeficiency virus (HIV) on highly active antiretroviral therapy (HAART) in resource poor settings is
important for proper planning, advocacy and resource allocation. We conducted a study to forecast 5-years
prevalence of any OI among HIV-infected individuals on HAART in Uganda.
Methods: Monthly observational data collected over a 10-years period (2004–2013) by the AIDS support organization
(TASO) in Uganda were used to forecast 5-years annual prevalence of any OI covering the period 2014–2018. The OIs
considered include 14 AIDS-defining OIs, two non-AIDS defining OIs (malaria & geohelminths) and HIV-associated
Kaposi’s sarcoma. Box-Jenkins autoregressive integrated moving average (ARIMA) forecasting methodology was used.
Results: Between 2004 and 2013, a total of 36,133 HIV patients were enrolled on HAART of which two thirds (66 %)
were female. Mean annual prevalence for any OI in 2004 was 57.6 % and in 2013 was 27.5 % (X2trend = 122, b = −0.0283,
p <0.0001). ARIMA (1, 1, 1) model was the most parsimonious and best fit for the data. The forecasted mean annual
prevalence of any OI was 26.1 % (95 % CI 21.1–31.0 %) in 2014 and 15.3 % (95 % CI 10.4–20.3 %) in 2018.
Conclusions: While the prevalence of any OI among HIV positive individuals on HAART in Uganda is expected to
decrease overall, it’s unlikely that OIs will be completely eliminated in the foreseeable future. There is therefore
need for continued efforts in prevention and control of opportunistic infections in all HIV/AIDS care programmes
in these settings.
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Background
Since the introduction of highly active antiretroviral
therapy (HAART) in resource poor settings, there has
been tremendous reduction in the incidence and overall
prevalence OIs among persons living with HIV/AIDS
[1]. In 2014, UNAIDS came up with very ambitious
programme code named “90-90-90” meaning 90 % of all
the people living with HIV to be diagnosed, 90 % of all
diagnosed to receive ART and 90 % of all on ART to
have a fully suppressed viral load by 2020 [2]. Basing on
these targets and past achievements, there is global
consensus that the HIV/AIDS epidemic could be halted
by 2030 if the planned actions are fully implemented [3].
These targets have been adopted by many developing
countries including Uganda and form the basis for na-
tional policy and strategic planning. Uganda 5 year
National HIV strategic plan (2015/16-2019/2020) (NSP)
targets to reduce HIV-associated morbidity and mortal-
ity by 70 % and maintain 90 % viral suppression through
a strategy of increased HAART coverage, early HAART
initiation and improved retention in HIV care [4, 5].
HAART rollout in public funded HIV/AIDS care facil-
ities in Uganda started in 2004 as part of the Global
HAART roll out strategy [6]. The Uganda government
employed a public-private sector partnership strategy to
accelerate the HAART rollout exercise. By the end of
2014, a cumulative total of 750,896 HIV positive patients
out of the estimated 1.6 million HIV positive individuals
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in Uganda (50 %) had access to HAART [4]. However,
despite these impressive gains, there are still disparities
in HAART usage by geographical area, sex and age [5]
and the effect of increasing HAART coverage on fre-
quency and patterns of OIs among HIV positive individ-
uals over time and in different geographical areas is not
well known.
Effective strategies for prevention of opportunistic
infections and mortality associated with HIV/AIDS is
of great importance given the high cost and uncer-
tainty surrounding sustainability of lifelong ART in
resource poor settings. There is therefore need to
plan ahead of time in order to make current treat-
ment/preventive interventions more effective. An
accurate morbidity prediction of any OI among HIV-
infected patients on HAART provides a good scien-
tific basis for planning and formulating appropriate
control or preventive policies.
The Box-Jenkins autoregressive integrated moving
average (ARIMA) model is the most widely used method
in forecasting of infectious diseases [7–14]. ARIMA fits
univariate models for a time series where time
dependent disturbances are allowed to follow a linear
autoregressive moving average specification [15, 16].
Univariate ARIMA forecasting is a procedure for com-
puting a forecast based on past and present values of a
given series possibly augmented with a function of time
(e.g. a linear trend) [16]. However, univariate ARIMA
forecasting is appropriate where there is large number of
series to forecast and the time series are stationary (i.e.
constant variance or rate of change). ARIMA models
have been used successfully to monitor and forecast dif-
ferent infectious diseases including new annual HIV in-
fections in Korea [17], monthly dengue fever cases in
Thailand [9], monthly dengue incidence in Brazil [12],
hantavirus outbreak in Chile [13], SARs outbreak in
Singapore [11], hemorrhagic fever outbreak in China
[10], monthly malaria cases in Burundi [14], monthly TB
morbidity in China [7] and monthly mortality rate in
under-five years old children in Iran [18].
However to the best of our knowledge, there has
not been any published work on prediction of OIs
associated with HIV/AIDS among HIV positive pa-
tients on HAART in Uganda. The purpose of the
current study therefore was to model and forecast the
prevalence of any OI among HIV-infected individuals




Data for this study was obtained from the AIDS Support
Organization (TASO) in Uganda. TASO is the oldest
and largest non-governmental organization (NGO)
providing HIV/AIDS care and treatment in Uganda and
sub-Saharan Africa [19]. TASO started in 1987 and has
since established 11 HIV clinics spread across Uganda
serving mainly the rural population [20]. TASO HIV/
AIDS care and treatment programme offers a wide range
of services include HIV testing and counseling, anti-
retroviral therapy, primary and secondary prophylaxis,
OI diagnosis and treatment, home based care and
psycho-social support.
With close to 3 decades of experience in HIV/AIDS
care and treatment, TASO provided a good opportunity
for assessing HAART effect on trends of opportunistic
infections in real life programmatic settings in which
HAART roll out is taking place in sub-Saharan Africa
[21]. Initially, access to HAART was based on the
Ugandan ministry of Health and the World Health
Organization (WHO) 2006 guide lines as indicated
above [22, 23]. However, after 2010 access to HAART
was expanded to include HIV patients with CD4 cell
count ≤350 or WHO clinical stage3 or 4 irrespective of
CD4 cell count as was recommended by Ugandan
Ministry of Health and WHO/UNAIDS [24, 25]. By
end of 2013, a total of 91,218 were actively in care of
which 58,051 clients(64 %) were on HAART and
87,903(96.4 %) were on cotrimoxazole/dapson prophylaxis
throughout the 11 HIV clinics across Uganda [20]. All ser-
vices are free of charge including anti-retroviral drugs
(ARVs) for those who are eligible [21].
Sampling and sample size
Four TASO HIV clinics were purposively selected
basing on volume, quality of data and geographical
representation. The HIV clinics selected were TASO
Mulago HIV clinic in central Uganda, TASO Mbarara
HIV clinic in south-western Uganda, TASO Tororo
HIV clinic in Eastern Uganda and TASO Gulu HIV
clinic in Northern Uganda (Fig. 1). All HIV positive
adults (15 years and above) who attended at least
once at the selected HIV clinics in the period from
1st January 2004 to 31stDecember 2013 were included
in the study.
Data collection
Data collection procedure was according to an estab-
lished protocol across all TASO HIV clinics. In brief,
each client is expected to attend the clinic at least once
a month. At each clinic visit, data per client is collected
on a standardized case report form (CRF) detailing the
client’s demographic characteristics, clinical condition,
medical history, prophylaxis use, OI diagnosis and treat-
ment given. The information was then compiled and en-
tered into the TASO electronic data base using EPIINFO
vs3 in Access format. Data on 14 AIDS-defining OIs and
2 non-AIDS defining OIs (malaria & geohelminths) plus
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HIV-associated Kaposi’s sarcoma were compiled and
handed over for analysis.
Statistical analysis
To establish whether there is a trend, data on prevalence
of any OI was summarized by month and calendar year.
Then a monthly time plot was drawn. Monthly preva-
lence was calculated as a proportion of clients diagnosed
with any OI in a given month. Mean annual prevalence
was calculated as an average of the 12 monthly preva-
lences in a year. To examine long term trends in
monthly prevalence, the moving average smoothing
technique was used to filter out short-term fluctuations
and random variation within the monthly series [26].
The moving average smoothing technique achieves this
by replacing each element of the time series by n neigh-
bouring elements, where n is the width of the smoothing
window. A centered moving average including three ob-
servations before and two observations after the current
observation inclusive was used.
To forecast, the Box-Jenkins ARIMA methodology
[27] was used. This method involves an interactive pro-
cedure including: model identification, evaluation and
diagnostic checking before forecasting. Since ARIMA
requires a stationary process, the Augmented Dickey-
Fuller (ADF) unit-root test was used to test for station-
arity of the monthly series. Non-stationary series were
transformed by first order differencing to stabilize the
variance. Autocorrelation function (ACF) and partial
autocorrelation function (PACF) plots were used to de-
termine possible values for the autoregressive and mov-
ing average orders. Akaike information criterion (AIC)
and Bayesian information criterion (BIC) were used to
identify the most parsimonious model. Parameter esti-
mation was by maximum likelihood method. Diagnostic
checks involved plotting ACF and PACF for autocorrel-
ation structure and the Portmanteau test for white noise
in the model residuals.
In order to evaluate the model forecast accuracy, data
were split into two groups: one for the fitting process
Fig. 1 Map of Uganda showing the location of study sites
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(2004–2010) and the other for validation (2011–2013).
Forecast accuracy was assessed by computing the mean
absolute percentage error (MAPE) [16]. Finally, the fitted
ARIMA model was used to forecast 5 year mean
prevalence of any OI among HIV positive patients on
HAART for the period 2014–2018. Root mean squared
error (RMSE) was used to estimate lower and upper
forecast limits [28]. All analyses were conducted using
Table 1 Baseline characteristics of study participants who were started on HAART in the period between 2004 and 2013
Variable Total Female Male p-value
Gender (36,133), n(%)
Female 23,767(66) - - -
Male 12,366(34)
Median age(36,120), n(IQR) 33(27–40) 32(26–39) 36(29–43) <0.0001
Age (36,120), n(%)
<35 years 19,338 (54) 13,894 (58) 5444 (44) <0.0001
>=35 years 16,782 (46) 9863 (42) 6919 (56)
Location (36,133), n(%)
Eastern 9793(27) 6271 (26) 3522(28) <0.0001
Central 9493(26) 6573(28) 2920(24)
Western 8576(24) 5426(23) 3150(25)
Northern 8271(23) 5497(23) 2774(23)
Education (n = 34,337), n(%)
Primary/none 26,331(77) 18,165(81) 8166(69) <0.0001
>=Secondary 8006(23) 4342(19) 3664(31)
Marital status (n = 34,338), n(%)
Single/never married 2148(6) 1260(6) 888(7) <0.0001
Married 17,187(50) 9523(42) 7664(65)
Divorced 5778(17) 4342(19) 1436(12)
Widowed 6932(20) 6118(27) 814(7)
others 2293(7) 1254(6) 1039(9)
Occupation (n = 33,454), n(%)
Paid employee 5731(17) 2611(12) 3120(27) <0.0001
Self employed 12,157(36) 9193(42) 2964(26)
Subsistence farmer 13,283(40) 8855(40) 4428(38)
others 2283(7) 1196(6) 1087(9)
WHO clinical stage (n = 36, 133), n(%)
I&II 16,535 (28.5) 11,030 (28.5) 5505 (28.6) 0.773
III&IV 41,410 (71.5) 27,675 (71.5) 13,735 (71.4)
Weight (23,848), n(%)
<55 years 11,853(50) 8156(52) 3697(45) <0.0001
>=55 years 11,995(50) 7466(48) 3697(55)
ART regimes
Stavudine 3926(11) 2743(11) 1183(10)
Zidovudine 18,142(50) 11,881(50) 6261(50) <0.0001
Tenofovir 9931(28) 6397(27) 3534(29)
Other 4134(11) 2746(12) 1388(11)
Year of enrolment on HAART
2004–2008 12,433(34) 8439(36) 3994(32) <0.0001
2009–2013 23,700(66) 15,328(64) 8372(68)
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Stata 13 (Stata Corp, TX) with p <0.05 considered
significant.
Results
Between 2004 and 2013, a total of 36,133 HIV patients
were enrolled on HAART of which two thirds (66 %)
were female with a median age of 33 year (IQR, 27–
40) (Table 1). In the planning data (2004–2010), it
was observed that mean annual any OI prevalence re-
duced from 56.62 % in 2004 to 36.61 % in 2010.
While in the validation data (2011–2013) mean
annual any OI prevalence reduced from 35.89 % in
2011 to 27.53 % in 2013 (Table 2).
A time plot of the monthly OI prevalence trends
shows several minor peaks along the series (Fig. 2). No
seasonal or periodic components were clearly seen in
the plot but the smoothed series generally depict a de-
creasing trend (Z statistic = −10.23, p <0.0001, nptrend)
(Fig. 2). The Augmented Dickey-Fuller (ADF) test
shows that the original monthly series had a unit root
(z (t) = −2.353, p = 0.1556, lags = 20) suggesting that it’s
not stationary. However after the first differencing the
ADF test rejected the null hypothesis of a unit root in
the series (z (t) = −16.7, p <0.001, lags = 20) implying
that the differenced monthly series were stationary
(Fig. 2). All further statistical procedures were per-
formed on the stationary series.
Table 2 Mean annual prevalence of any OI (2004–2013)
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Fig. 2 Plot showing (a) the original and smoothed any OI monthly prevalence series and (b) first order differenced any OI monthly prevalence
series (2004–2013)
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Model identification started with autocorrelation ana-
lysis. Plots of autocorrelation function (ACF) and partial
autocorrelation function (PACF) (Fig. 3) showed only
the first lag of the ACF was significant (i.e. laying outside
the grey 95 % CI band). It was also observed that the
first few lags of PACF were decaying with time. Based
on the autocorrelation structure, several potential
models were identified.
Using the Akaike information criteria (AIC) and
Bayesian information criteria (BIC), several first order
differenced models were evaluated. ARIMA (1, 1, 1),
ARIMA (1, 1, 2) and ARIMA (2,1,1) were initially se-
lected basing on their low AIC and BIC values (Table 3).
Fig. 3 Plot of autocorrelation function (ACF) and partial autocorrelation function (PACF) for the first order differenced any OI monthly series
Table 3 AIC and BIC model selection criteria
Model AIC BIC Rank
ARIMA (1,1,1) 870 881 1
ARIMA (1,2,1) 870 882 2
ARIMA (1,2,3) 870 884 3
ARIMA (1 1 3) 870 884 3
ARIMA (2,2,1) 870 884 3
ARIMA (2 1 1) 870 884 3
ARIMA (3, 2, 4) 870 889 4
ARIMA (1,2,2) 871 885 5
ARIMA (1 1 2) 871 885 5
ARIMA (3,2,3) 871 893 6
ARIMA (3 1 3) 871 893 6
ARIMA (2,2,2) 872 889 7
ARIMA (2 1 2) 872 889 7
ARIMA (3,2,1) 872 889 7
ARIMA (3 1 1) 872 889 7
ARIMA (4 1 3) 872 894 8
ARIMA (2 1 4) 873 895 9
Table 4 Estimation of model parameters for any OI
Model Model parameter Coefficient p-value
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Parameter estimation for ARIMA (1, 1, 1), showed that
AR (1) coefficient of 0.23 and MA (1) coefficient of
−0.86 were significant (p <0.05) (Table 4).
Plots of autocorrelation function (ACF) and partial
autocorrelation (PACF) of the model residuals showed
that ACFs and PACFs were not significantly different
from zero (white noise) (Fig. 4). The portmanteau Q-test
(Q15 = 8.20, p = 0.9153) was also in favour of the null hy-
pothesis of no autocorrelation in the residuals. A plot of
the residual histogram showed no volatility clustering
and so assumed the residuals were homoscedastic
(Fig. 5). The skewness-kurtosis test (X2 = 3.42, p = 0.154)
was consistent with the normality assumption of the
model residuals (Fig. 4.13).
Fig. 4 Plot of residuals autocorrelation function (ACF) and partial autocorrelation (PACF) for the fitted model to forecast any OI prevalence
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Fig. 5 Histogram of the residuals
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Average annual prevalence rates declined from 58 % in
2004 when HAART was first rolled out to 28 % in 2013.
The model estimated a decline in OI rate of −0.028 per
year (95 % CI −0.034 to −0.023) or −0.0023 per month
(95 % CI: −0.0028 to −0.0019).
A plot of the observed and predicted values of any OI
matched reasonably well (Fig. 6). A t-test of the observed
and predicted mean annual any OI prevalence showed
no significant difference (p >0.05) (Table 5). The pre-
dicted linear trend from the model and the fitted linear
trend to the observed data had the same slope = −0.0023
(95 % CI: −0.0028 to −0.0019) (Fig. 7).
The forecasted mean annual prevalence of any OI was
26.1 % (95 % CI 21.1–31.0 %) in 2014 and 15.3 % (95 %
CI 10.4–20.3 %) in 2018 (Table 6). The prediction error
estimated in terms of mean absolute percentage error
(MAPE) was 8.2 % (SD = 6.0).
Discussion
ARIMA models have been widely used to predict mor-
bidity and mortality due to infectious diseases with
fairly good accuracy [7, 9, 10, 12, 17]. Early warning
based on forecasts is very important for advocacy and
resource allocation. For example ARIMA models have
been successfully used to monitor and forecast new an-
nual HIV infections in Korea [17], monthly dengue
fever cases in Thailand [9], monthly dengue incidence
in Brazil [12], hantavirus outbreak in Chile [13], SARs
outbreak in Singapore [11], hemorrhagic fever outbreak
in China [10], monthly malaria cases in Burundi [14],
monthly TB morbidity in China [7] and monthly mor-
tality rate in under-five years old children in Iran [18].
Yu et al. [17] used observation data for the period
1985–2012 to forecast new HIV infections for the
period 2013–2017. ARIMA models can take into ac-
count changing trends, periodic changes and random
disturbances in the time series [7].
This study established that ARIMA (1,1,1) can be used
to predict monthly OI morbidity among HIV positive
patients on HAART in Uganda. The fitted model sug-
gests the need for first-order differencing of the series to
remove a stochastic decreasing trend, then a first order
autoregressive (1) term and a first order moving average
(1) term to cater for serial correlation in the data. This
means that prevalence of any OI each month is directly
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Fig. 6 Plot of observed and predicted values for any OI among HIV positive patients on HAART from the fitted ARIMA (1, 1, 1) model with their
corresponding 95 % confidence limits
Table 5 t-test of the difference between observed and predicted mean annual any OI prevalence in the validation period (2011–2013)
Year Observed Predicted t-test
Mean annual any OI prevalence SD Mean annual any OI prevalence SD
2010 36.61 2.25 36.39 0.923 t = 1.5421, p = 0.151
2011 35.89 2.83 36.12 1.501 t = −0.620, p = 0.547
2012 34.16 3.52 34.21 1.404 t = −0.035, p = 0.973
2013 27.53 2.15 27.84 1.601 t = −0.519, p = 0.614
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month and the prediction errors of the current and pre-
ceding month. The model can also be used to estimate
the cost of OIs prevention/treatment in the next 5 years
of HAART after 2013 as well as informing policy, plan-
ning and advocacy for increased resource allocation
towards HIV/AIDS care in Uganda.
In this study, the forecasted prevalence of any OI was
15.3 % in 2018 which show that though the prevalence
of any OI is likely to reduce but will not vanish as was
reported in previous studies elsewhere [29]. Available
reports suggest that OIs are likely to remain an import-
ant aspect of care even in the era of HAART especially
in low income countries due to several factors includ-
ing late HIV diagnosis, sub-optimal HAART use, poor
adherence, dug resistance, poverty, poor nutrition, high
exposure to infectious agents, just to mention a few
[29–35]. Early warning based on forecasts is very im-
portant for future planning and rational resource allo-
cation. There is therefore need for more efforts in
prevention and control of opportunistic infections in all
HIV/AIDS care programmes in these settings.
In the current study, results show that the ARIMA (1,1,1)
model gives a good prediction of OIs prevalence in the
period January 2014 - December 2018 (60 months) within
8 % margin of error i.e. MAPE = 8.2. The prediction error
was close to that found in another previous study that used
ARIMA (3,1,4) model to forecast dengue incidence in
North-Eastern Thailand with a margin of error of 7 % (i.e.
MAPE = 7.0) [36]. The difference could be attribute to the
fact that our predictions covered a slightly longer period of
60 months compared to 40 months in the previous study.
One of the limitation of this study was that the ARIMA
model was fitted with a constant term (1st order differ-
ences) hence forcing the assumption that past trends (a
reduction of 0.2 % in OI prevalence per month) will be
maintained over time. This could only be possible if the
current OI interventions are maintained and all other fac-
tors remain constant which may not be the case. Future
studies should explore the effect of other time changing
variables (HAART access policy, OI treatment/ prophy-
laxis, adherence, drug resistance, etc.) on the trends. Pro-
jections using alternative models such as ARIMA models
without a constant term can also be explored in the
future. Another limitation was that, although the model
adequacy was evaluated, ARIMA models can only be used
for short term forecasts and the accuracy of the predicted
values gets less the longer the prediction period.
Despite the above limitations, the greatest strength
of the present study is that it is the first in Uganda
to model and predict out-of-sample prevalence of OIs
among HIV positive patients on HAART. However,
additional studies from other ART programmes in the
country are needed in order to generalize the results
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Observed data Fitted linear trend
ARIMA(1,1,1) predicted linear  trend 95% upper prediction limit
95% lower prediction limit
Slope (per month) =  - 0.0023
(95 CI : -0.0028  to -0.0019)
Fig. 7 Scatter plot of observed data with fitted linear trend and ARIMA (1,1,1) predicted trend with 95 % confidence intervals
Table 6 One-step ahead forecast of mean annual prevalence of
any OI among HIV positive patients on HAART (2014–2018)
Time Predicted
value (per 100)
95 % Confidence limits
Lower predicted limit Upper predicted limit
2014 26.1 21.1 31.0
2015 23.3 18.3 28.3
2016 20.7 15.7 25.6
2017 18.0 13.0 23.0
2018 15.3 10.4 20.3
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Conclusion
While the prevalence of any OI among HIV positive indi-
viduals on HAART in Uganda is expected to decrease
overall, it’s unlikely that OIs will be completely eliminated
in the foreseeable future. There is urgent need to integrate
control/prevention measures for all OIs in HIV/AIDS care
programmes and to address all factors that may under-
mine HAART effect including poverty if OIs are to be
eliminated in these settings. The forecast model in the
current study could be the first attempt to predict morbid-
ity due to OIs among HIV positive individuals on HAART
in Uganda. However, ARIMA models are designed for
short term forecasts. Future observational series should
explore other predictive models that provide longer fore-
casts taking into account time changing variables and ran-
dom disturbances in the time series.
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